Natalie Johnson
Program: Unspecified
Current advisor: Rotating in the lab of Carl DeSelm, MD, PhD
Undergraduate university: Oregon State University
Research summary
During my 4-week lab rotation, I examined the role of TLR4 signaling pathways, specifically MyD88 and TRIF, in dendritic cell (DC)-mediated tumor rejection. Using CRISPR/Cas9 technology and sgRNAs targeting MyD88 and TRIF, I performed gene knockouts in primary conventional type 1 dendritic cells (cDC1s). Through T-cell activation, I characterized the functional phenotype of these modified dendritic cells in the context of anti-tumor immune responses.
Graduate publications